Targeted immunotherapy of psoriasis: focusing on Janus kinase/signal transducers and activators of transcription signaling pathway

IF 6.6 2区医学 Q1 IMMUNOLOGY

Current Opinion in Immunology Pub Date : 2025-05-31 DOI:10.1016/j.coi.2025.102583

Zeyu Chen , Suyang Lin , Lian Cui , Qian Yu , Yuling Shi

{"title":"Targeted immunotherapy of psoriasis: focusing on Janus kinase/signal transducers and activators of transcription signaling pathway","authors":"Zeyu Chen , Suyang Lin , Lian Cui , Qian Yu , Yuling Shi","doi":"10.1016/j.coi.2025.102583","DOIUrl":null,"url":null,"abstract":"<div><div>Psoriasis is a chronic inflammatory skin condition that affects approximately 1%–3% of the global population. The advent of biologic therapies has markedly improved the management of moderate-to-severe cases. While the efficacy and safety of these novel agents are well documented, many patients value the convenience of oral therapies, which not only eliminate the risk of injection site infections and complications but also alleviate the fear and discomfort associated with needles. The Janus kinase (JAK)/signal transducers and activators of transcription (STAT) signaling pathway plays a crucial role in mediating the psoriatic inflammatory responses. Current research is focused on developing oral therapies, particularly JAK/STAT inhibitors, that provide improved efficacy and safety. In contrast to existing reviews, our scoping review not only evaluates randomized controlled trials of pan-JAK, selective JAK, and selective tyrosine kinase 2 inhibitors but also delves into mechanistic insights regarding both therapeutic effects and mechanisms of relapse.</div></div>","PeriodicalId":11361,"journal":{"name":"Current Opinion in Immunology","volume":"95 ","pages":"Article 102583"},"PeriodicalIF":6.6000,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Immunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0952791525000597","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Psoriasis is a chronic inflammatory skin condition that affects approximately 1%–3% of the global population. The advent of biologic therapies has markedly improved the management of moderate-to-severe cases. While the efficacy and safety of these novel agents are well documented, many patients value the convenience of oral therapies, which not only eliminate the risk of injection site infections and complications but also alleviate the fear and discomfort associated with needles. The Janus kinase (JAK)/signal transducers and activators of transcription (STAT) signaling pathway plays a crucial role in mediating the psoriatic inflammatory responses. Current research is focused on developing oral therapies, particularly JAK/STAT inhibitors, that provide improved efficacy and safety. In contrast to existing reviews, our scoping review not only evaluates randomized controlled trials of pan-JAK, selective JAK, and selective tyrosine kinase 2 inhibitors but also delves into mechanistic insights regarding both therapeutic effects and mechanisms of relapse.

查看原文本刊更多论文

银屑病的靶向免疫治疗：聚焦于Janus激酶/信号转导和转录信号通路的激活因子

牛皮癣是一种慢性炎症性皮肤病，影响全球约1%-3%的人口。生物疗法的出现显著改善了中重度病例的治疗。虽然这些新型药物的疗效和安全性得到了充分的证明，但许多患者更重视口服治疗的便利性，因为口服治疗不仅可以消除注射部位感染和并发症的风险，还可以减轻与针头相关的恐惧和不适。Janus kinase (JAK)/signal transducers and activators of transcription （STAT）信号通路在介导银屑病炎症反应中起着至关重要的作用。目前的研究重点是开发口服疗法，特别是JAK/STAT抑制剂，以提高疗效和安全性。与现有的综述相比，我们的范围综述不仅评估了泛JAK、选择性JAK和选择性酪氨酸激酶2抑制剂的随机对照试验，还深入研究了治疗效果和复发机制的机制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in Immunology 医学-免疫学

CiteScore

13.30

自引率

1.40%

发文量

审稿时长

67 days

期刊介绍： Current Opinion in Immunology aims to stimulate scientifically grounded, interdisciplinary, multi-scale debate and exchange of ideas. It contains polished, concise and timely reviews and opinions, with particular emphasis on those articles published in the past two years. In addition to describing recent trends, the authors are encouraged to give their subjective opinion of the topics discussed. In Current Opinion in Immunology we help the reader by providing in a systematic manner: 1. The views of experts on current advances in their field in a clear and readable form. 2. Evaluations of the most interesting papers, annotated by experts, from the great wealth of original publications. Current Opinion in Immunology will serve as an invaluable source of information for researchers, lecturers, teachers, professionals, policy makers and students. Current Opinion in Immunology builds on Elsevier''s reputation for excellence in scientific publishing and long-standing commitment to communicating reproducible biomedical research targeted at improving human health. It is a companion to the new Gold Open Access journal Current Research in Immunology and is part of the Current Opinion and Research(CO+RE) suite of journals. All CO+RE journals leverage the Current Opinion legacy-of editorial excellence, high-impact, and global reach-to ensure they are a widely read resource that is integral to scientists'' workflow.